Photocure ASA Appoints Jane Healy as EMEA Vice President
OSLO, Norway, March 26, 2025 /PRNewswire/ — Photocure ASA PHO, known as the Bladder Cancer Company, has appointed Jane Healy as Vice President and General Manager for EMEA.
Ms. Healy’s Extensive Experience in the Medical Device Sector
Joining Photocure in March 2025, Ms. Healy will lead the European organization. Her background spans over 30 years in the medical device industry, with significant roles in sales, marketing, general management, and functional leadership. She has previously held key positions at St Jude Medical, CR Bard, and Boston Scientific.
Most recently, Jane Healy served as VP EMEA for the Peripheral Interventions Division at Boston Scientific, directly overseeing regional growth strategies. Her strong commercial insights and results-driven approach demonstrate her commitment to fostering team success. She holds a BA (Hons) in Modern Languages from Cambridge University and is proficient in English, French, German, and Italian.
Leadership Perspective
“I am pleased to welcome Jane to the Photocure team at such an important time for us,” said Dan Schneider, President and CEO of Photocure. “Her extensive experience in healthcare and medical devices will play a vital role in reaching our growth goals in uro-oncology. Jane is well-suited to lead our European organization, especially as the Uro-Oncology field sees significant innovation. She will report directly to me and join Photocure’s executive leadership team.”
Growing The European Organization
The establishment of Photocure’s European Organization followed the decision to regain the sales, marketing, and distribution rights for Hexvix® from Ipsen Pharma SAS on October 1, 2020. Since then, the team has increased momentum in reintroducing Blue Light Cystoscopy (BLC) to the European market.
“I am excited about the ongoing advancements in Europe and anticipate Jane’s leadership as we continue to strive for transformative changes in bladder cancer care,” Schneider concluded. “The use of Blue Light Cystoscopy is crucial in accurately diagnosing bladder cancer, as it optimizes staging and treatment planning.”
Important Information for Editors
Note to editors: All trademarks mentioned in this release are legally protected and registered trademarks of Photocure ASA. This press release may include product details or information that are not available or compliant with regulations in particular countries. Photocure assumes no responsibility for access to any such information.
About Bladder Cancer
Bladder cancer is the 8th most prevalent cancer globally and the 5th most common in men, with 1,949,000 prevalent cases (5-year prevalence rate) and 614,000 new diagnoses alongside over 220,000 deaths in 2022.
Approximately 75% of bladder cancer cases occur in men. The disease is characterized by high recurrence rates, with up to 61% in the first year and reaching 78% over five years. Bladder cancer treatment is associated with the highest lifetime costs per patient of any cancer.
Given its costly nature and potential for progression, bladder cancer patients often undergo multiple cystoscopies due to recurrence risks. Thus, there’s an urgent need for improved diagnosis and management strategies to benefit both patients and healthcare systems.
Bladder cancer is categorized into two types: non-muscle invasive bladder cancer (NMIBC) and muscle-invasive bladder cancer (MIBC), determined by the cancer’s invasion depth. NMIBC remains confined to the bladder’s inner cell layer, comprising 75% of all cases, while MIBC invades deeper layers and presents greater treatment challenges.
About Hexvix®/Cysview® (hexaminolevulinate HCl)
Hexvix/Cysview is a drug specifically designed to accumulate in bladder cancer cells, causing them to fluoresce pink during Blue Light Cystoscopy (BLC®). This technique improves tumor detection, enables more comprehensive resections, and supports informed management decisions when compared to standard white light cystoscopy.
While Cysview is the brand name used in the U.S. and Canada, Hexvix is used in all other markets. Photocure is actively commercializing Cysview/Hexvix.
Photocure Appoints New VP and General Manager for EMEA Region
Photocure ASA has recently announced the appointment of Jane Healy as the Vice President and General Manager for the EMEA region. This strategic move is part of the company’s continued efforts to enhance its presence in key markets, including the U.S. and Europe, where it has established partnerships for the commercialization of its products Hexvix and Cysview.
Expanding Global Partnerships
Photocure’s strategic partnerships extend beyond Europe and the U.S. for the commercialization of Hexvix and Cysview. The company also aims to broaden its market reach into China, Chile, Australia, New Zealand, and Israel. For more information on their commercial collaborations, please visit Photocure’s partners page.
About Photocure ASA
Photocure: The Bladder Cancer Company is committed to providing transformative solutions that enhance the health outcomes of bladder cancer patients. Utilizing proprietary technology that causes cancer cells to glow bright pink, Photocure has positively impacted patient care globally. Headquartered in Oslo, Norway, Photocure is publicly traded on the Oslo Stock Exchange under the ticker PHO. For further details, visit our news portal.
Contact Information
For additional inquiries, please reach out to:
Dan Schneider
President and CEO
Photocure ASA
Email: [email protected]
Erik Dahl
CFO
Photocure ASA
Tel: +47 450 55 000
Email: [email protected]
Media and Investor Relations:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 915 40 000
Email: [email protected]
This update was shared through Cision. For the original press release, visit this link.
© 2025 Benzinga.com. Please note that Benzinga does not provide investment advice. All rights reserved.
